AUTH/2461/12/11: Anonymous v AstraZeneca — complaint about representative conduct (no breach)

📅 2011 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/2461/12/11
PartiesAnonymous v AstraZeneca
IssueConduct of a representative (professionalism, access behaviour, alleged diary distribution, alleged discussion of an unlicensed medicine)
Complaint received02 December 2011
Case completed05 January 2011 (as stated in the case material)
Applicable Code year2011
Clauses considered2, 3.1, 15.2, 15.4, 15.9, 18.1, 9.1
OutcomeNo breach of the Code
AppealNo appeal
Additional sanctionsNone stated

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • An anonymous complainant (described as a “very disappointed practice manager”) questioned the integrity and professionalism of an AstraZeneca representative.
  • Allegations included: rudeness/ill-mannered conduct, lack of respect for busy schedules, lateness to meetings, intimidating reception staff, and waiting for doctors in car parks to speak to them.
  • The complainant alleged the representative gave out diaries with meeting/lunch dates already pencilled in.
  • The complainant alleged the representative spoke to a doctor about a type 2 diabetes medicine that was “not even licensed in the UK”.
  • AstraZeneca investigated (interviewed the representative, managers, colleagues/partners and health professionals) and stated it found no evidence to support the allegations; the representative denied key points (car park conversations, diary distribution, unlicensed promotion).
  • AstraZeneca noted the representative’s manner was regarded by some as “slightly eccentric”, producing varied reactions; managers had coached the representative.
  • The Panel noted the complainant was anonymous and non-contactable, and provided no evidence; this limited the ability to test disputed factual claims.
⚖️

Outcome

  • No breach of the Code was ruled.
  • No breach of Clauses 15.2 and 15.4 (representative conduct / not causing inconvenience).
  • No breach of Clause 18.1 (provision of diaries/promotional aids as alleged).
  • No breach of Clauses 3.1 and 15.9 (promotion of an unlicensed medicine as alleged).
  • No breach of Clause 9.1 and consequently no breach of Clause 2.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training